Quantcast

Latest Actavis Stories

2014-03-06 08:32:02

LAS VEGAS, March 6, 2014 /PRNewswire/ - Vansen Pharma Inc. [OTCQB: VNSN] is pleased to announce the appointment of Mr. Ali Moghaddam to its Board of Advisors. Mr. Moghaddam is an accomplished pharmaceutical executive with over 25 years of experience in both Canada and the U.S., having played a transformational role with companies such as Bristol- Myers Squibb Canada, Linson Pharma Inc. (generic business unit of BMS), Allergan Canada, and E-Z-EM Inc. U.S. (now part of Bracco Group)....

2014-03-04 08:32:00

DUBLIN, March 4, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Barclays Global Healthcare Conference in Miami. The presentation will take place on Tuesday, March 11, 2014 at 9:30 AM Eastern Standard Time at the Lowes Miami Hotel, 1601 Collins Avenue, Miami, FL. To access a live webcast of the...

2014-03-03 08:30:41

BOSTON, Mar. 3, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Donald H. Hunter, an executive and technology consultant with over 25 years of public company experience, has been appointed to its Board of Directors. Mr. Hunter qualifies as a financial expert under the SEC guidelines, and will serve on the Company's audit committee. "Donald Hunter brings a wealth of experience in accounting and control, financial reporting, mergers and...

2014-02-28 16:23:59

DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colchicine Tablets USP, 0.6 mg. Actavis' ANDA product is a generic version of Takeda's Colcrys(®), which is a prescription medicine used in adults to prevent and treat gout flares. Takeda Pharmaceuticals U.S.A., Inc. filed suit against Actavis on February 27, 2014 in the...

2014-02-28 08:25:23

DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dronedarone Hydrochloride Tablets 400 mg. Actavis' ANDA product is a generic version of Sanofi's Multaq(®), which is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of...

2014-02-27 12:27:03

CHICAGO, Feb. 27, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Dr. Reddy's Laboratories Ltd. (NYSE:RDY-Free Report), Actavis plc (NYSE:ACT-Free Report), Amgen Inc. (Nasdaq:AMGN-Free Report), Biogen Idec Inc. (Nasdaq:BIIB-Free Report) and eBay Inc. (Nasdaq:EBAY-Free...

2014-02-26 08:27:54

BOSTON, Feb. 26, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on March 5, 2014, to discuss financial results of the fourth quarter and fiscal year ended December 31, 2013. Frank Condella, President and Chief Executive Officer, and Jonathan Lloyd Jones, Vice President and Chief Financial Officer of Columbia Laboratories, will host the call as follows: Date: Wednesday, March 5, 2014 Time: 8:30...

2014-02-20 08:29:17

- Fourth Quarter 2013 GAAP Loss Per Share of $0.86 - DUBLIN, Feb. 20, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today reported net revenue increased 59 percent to $2.779 billion for the fourth quarter ended December 31, 2013, compared to $1.75 billion in the fourth quarter 2012. On a non-GAAP basis, diluted earnings per share for the fourth quarter 2013 increased to $3.17, compared to $1.59 per diluted share in the fourth quarter 2012. GAAP loss per share for the fourth...

2014-02-19 16:25:03

DUBLIN, Feb. 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at Citi's 2014 Global Healthcare Conference in New York. The presentation will take place on Tuesday, February 25, 2014 at 2:40 PM Eastern Standard Time at the Hilton New York Hotel, 1335 Avenue of the Americas, New York, New York. To access a...

2014-02-18 16:26:50

DUBLIN, Feb. 18, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it intends to issue its fourth quarter and full-year 2013 earnings release as planned on Thursday, February 20, 2014, prior to the opening of the U.S. markets. However, following the Company's announcement earlier today regarding its proposed acquisition of Forest Laboratories, Inc., Actavis has elected not to conduct an earnings conference call to discuss the quarterly and full-year results. The...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related